Lineage Cell Therapeutics Inc. — Director's Dealing 2014

Mar 25, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2014-03-20

Reporting Person: Peabody Robert (Sr. VP, COO, and CFO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-03-20	Option to Purchase Common Shares	$3.51	J	100000	Acquired	2021-03-19	Common Shares (100000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares, no par value	30400	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Shares	$4.22	2020-02-19	Common Shares (100000)	100000	Direct
Option to Purchase Common Shares	$0.50	2014-10-09	Common Shares (475000)	475000	Direct

Footnotes

F1: Does not include shares that may be acquired upon the exercise of certain stock options.

F2: 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after March 20, 2014.

F3: 1/48th of the number of options will vest and become exercisable at the end of each full month of employment after January 1, 2013.

F4: 1/60th of the number of options became exercisable at the end of each full month of employment after October 10, 2007.